Drug development for multiple sclerosis (MS), as with any other neurological disease, faces
numerous challenges, with many drugs failing at various stages of development. The …

Summary Background Mesenchymal stem cells (MSCs), also known as mesenchymal
stromal cells, have been proposed as a promising therapeutic option for people with multiple …

Discussion. Natalizumab is a humanized recombinant monoclonal antibody interfering with
the interaction of VLA-4 with its natural ligand, vascular cell adhesion molecule (VCAM-1) …

ABSTRACT BACKGROUND Demyelination is a core pathological feature of multiple
sclerosis (MS) and spontaneous remyelination appears to be an important mechanism for …

Growing evidence points to a deregulated response to Epstein–Barr virus (EBV) in the
central nervous system of patients with multiple sclerosis (MS) as a possible cause of …

Background: Multiple sclerosis (MS) is characterized by central nervous system (CNS)
infiltration of T and B cells, excess inflammatory cytokine and chemokine production and …

Age of onset in multiple sclerosis (MS) exerts an influence on the course of disease. This
study examined whether global and regional brain volumes differed between “younger” and …

Pathological diagnosis remains the gold standard for the diagnosis of sporadic Creutzfeldt-
Jakob disease (sCJD), but being able to differentiate between CJD and non-prion diseases …

Soluble CD27 is a promising cerebrospinal fluid inflammatory biomarker in multiple
sclerosis. In this study, we investigate relevant immune and neuro-pathological features of …

A 59-year-old woman provided a 3-month history of decreased hearing in her right ear. One
month later, she developed a complete right-sided ptosis and progressive dysarthria. On …